Your session is about to expire
← Back to Search
Vorinostat + Temozolomide for Brain Cancer
Study Summary
This trial is studying the side effects and best dose of vorinostat when given with temozolomide to treat patients with malignant gliomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of cancer or blood cell disorders.It has been at least 3 weeks since my last radiation therapy.I haven't had any cancer except for basal or squamous cell skin cancer in the last 5 years.My condition worsened despite taking temozolomide.I do not have any active infections or serious illnesses.I have a condition that affects how drugs are broken down in my body.I am HIV positive and on antiretroviral therapy.My hemoglobin level is at least 10 g/dL, transfusions included.My steroid medication dose has been stable.I have recently used valproic acid.I have been diagnosed with a specific type of brain tumor.I can care for myself but may need occasional help.My low-grade brain tumor was later found to be cancerous.
- Group 1: Treatment (vorinostat, temozolomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What applications is Vorinostat generally employed for?
"With Vorinostat, nitrosourea treatment and progressive cutaneous t-cell lymphoma can be managed. Additionally, advance directives are within its scope of application."
Has the Vorinostat drug been authorized by the US Food and Drug Administration?
"As a Phase 1 trial, Vorinostat's safety has been tested to some degree but not extensively. Thus, it received a score of 1 as determined by our team at Power."
Could you please elucidate the scope of research surrounding Vorinostat?
"Currently, 235 studies are underway examining Vorinostat's effects. Of these active investigations, 24 have advanced to Phase 3 clinical trials. While the majority of research is occurring in Seoul Songpa, there exists an international network of 5392 sites running various tests on this medication."
What is the scope of this research project in terms of participants?
"Unfortunately, this trial is not currently accepting new participants. It was established on December 16th 2005 and last amended November 16th 2022. If you're seeking other studies related to brain cancer, there are 1047 trials open for recruitment; alternatively 235 clinical trials concerning Vorinostat also have spots available."
How many physical sites are participating in this experiment?
"Participants can enroll in this clinical trial at Wake Forest University Health Sciences (Winston-Salem, NC), Cleveland Clinic Foundation (Cleveland, OH) and Moffitt Cancer Center (Tampa, FL). Additionally, there are 18 other sites across the nation."
Are there remaining vacancies in this research program for participants?
"This particular trial is not presently seeking participants. The protocol was first published on December 16th 2005 with the most recent edits occurring on November 16th 2022. If you are interested in alternative trials, 1047 brain cancer studies and 235 Vorinostat tests are actively accepting patients."
Is this research pioneering a new field of inquiry?
"Since 2002, researchers have conducted over 235 clinical trials of Vorinostat in 971 cities and 37 countries; with the initial study sponsored by Schering-Plough. After this first test involving 60 patients, Phase 2 drug approval was granted for Vorinostat."
Share this study with friends
Copy Link
Messenger